Please login to the form below

Not currently logged in
Email:
Password:

market data

This page shows the latest market data news and features for those working in and with pharma, biotech and healthcare.

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

GSK could carve out a corner of the market on the strength of this data, but it is unlikely to make much headway on Lynparza, which dominates in the market. ... Also looking to carve a piece of the PARP inhibitor market in ovarian cancer is AbbVie, who

Latest news

  • AZ, Merck’s Lynparza scores market-expanding clinical success AZ, Merck’s Lynparza scores market-expanding clinical success

    PARP inhibitors came to market on the strength of data showing they destroy BRCA-mutated tumours through synthetic lethality, but the phase3trial enrolled women regardless of their genetic status. ... Approval in ovarian cancer patients regardless of

  • Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial

    Lilly plans to share the data from the study at upcoming scientific meetings and in journal publications. ... Lilly brought Taltz to market using data showing it clears 90% of lesions in more than two-thirds of patients within 12 weeks.

  • ACPs to lead gene therapies in haemophilia market growth ACPs to lead gene therapies in haemophilia market growth

    Replacement factors are the current standard-of-care, representing 97% of the total sales of the haemophilia market in 2018. ... with no history of inhibitors, and questions have already been raised about their limited long-term safety and efficacy data.

  • ViiV builds case for switching to its two-drug HIV combinations ViiV builds case for switching to its two-drug HIV combinations

    In the meantime, Gilead looks set to continue to dominate the market with its three-drug therapies, currently holding a 73% market share according to IQVIA data. ... Injectable option. Meanwhile, ViiV also had an update this week on another drug

  • Agencies big and small celebrate Communiqué wins Agencies big and small celebrate Communiqué wins

    It racked up category wins for Communication of Survey or Market Research Data, Integrated Non-Promotional Communications, Healthcare Collaborations and Partnerships and in Media Relations. ... Naming it a clear winner in the Communications Consultancy

More from news
Approximately 1 fully matching, plus 126 partially matching documents found.

Latest Intelligence

  • Patient journey mapping: exploring the clinical and the emotional journey Patient journey mapping: exploring the clinical and the emotional journey

    Immersing yourself in existing information, such as previous market research or exploring the disease area on social media platforms supports an initial data immersion exercise that can feed into a bespoke ... The data immersion and bespoke market

  • The evolution of real-world studies The evolution of real-world studies

    Pfizer brought Ibrance to market using data from randomised controlled trials (RCTs) in women, before supplementing that evidence with real- world data (RWD) in men to expand the label. ... Ibrance gained a new approval based on data from EHRs and other

  • Global direction, local application Global direction, local application

    The best source of this data is, of course, your local market teams and agency partners, so listen and learn from them. ... 2. Just as local market variance should help define global strategy, it is essential that global strategy can be easily refined

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    Centralised global or national marketing experts will focus on building core tools, market sizing and comparative metrics. ... They’ll leverage market simulation and testing to develop data-driven messaging and creative packages.

  • Brand teams: why are some smarter than others? Brand teams: why are some smarter than others?

    Compared to your rivals, you and your colleagues have similar backgrounds, use similar methods and work with more or less the same data bought from the same market research companies. ... 3.  Testing, when the hypotheses developed from the explicated

More from intelligence
Approximately 1 fully matching, plus 34 partially matching documents found.

Latest appointments

  • Future Thinking appoints Mohamed Muhsin as UK pharma head Future Thinking appoints Mohamed Muhsin as UK pharma head

    Muhsin joins from QuintilesIMS Health, where he was therapy lead, oncology and prior to that he was a senior market analyst at Roche. ... Both Muhsin and Bonrepaux-Caux will be focusing on expanding Future Thinking’s global footprint, technical

  • LaingBuisson names chairman and CEO LaingBuisson names chairman and CEO

    Former Health Secretary Stephen Dorrell and Henry Elphick join. LaingBuisson, a UK healthcare market intelligence provider, has named Stephen Dorrell and Henry Elphick as its chairman and chief executive officer, respectively. ... Elphick said:

  • Natasha Giordano joins PLx Pharma Natasha Giordano joins PLx Pharma

    I look forward to building on the compelling clinical data and initial market access work the PLx management team has begun and to successfully launching PL2200 Aspirin into the U.S. ... market in 2017.” .

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 58 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics